\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationHybrid + Eight European countries
ProgrammesThe EUDIS Defence Hackathon aims to gather local hosts to organise the DEFENDING AIRSPACE hackathon from 26 to 28 March 2026. This event will take place simultaneously in eight European countries and is designed for diverse entities such as universities and businesses to participate as hosts.
Organisers are currently seeking eight local hosts, including public or private entities, accelerators, incubators, and military test sites. Each selected host will receive increased funding of €60,000 to support the event and the necessary technical equipment.
Furthermore, host entities will have the flexibility to define one of the hackathon's challenges themselves.
An online information session is scheduled for 12 January 2026, at 11:30 CET, with the link to be shared in early January.
The deadline for submitting applications is 25 January 2026 at 23:59 CET. More information can be found here: https://Join our upcoming edition - March 2026 - Eudis Defence Hackathon. and in the applicant guide: EUDIS-2026-Guide-for-Applicants_vFinal-1.pdf.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
